BRAF and melanoma: Continuous exposure to MAPK-targeted therapies, such as BRAF and MEK inhibitors (BRAFis and MEKis), can trigger metabolic reprogramming to promote cell state transitions, known as phenotype plasticity, enabling melanoma cells to persist, ultimately contributing to disease relapse.